Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00800618 | A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women | PHASE1 | COMPLETED | 42 | — | — | Nov 1, 2008 | Jun 1, 2009 | Feb 10, 2010 | 4 | United States, Belgium |
| Arm | Type | Description |
|---|---|---|
| PF-02413873 | EXPERIMENTAL | PF-2413873 active treatment |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| PF-02413873 100 mg QD | DRUG | 100 mg of PF-02413873 oral suspension once daily for 14 days |
| PF-02413873 1500 mg QD | DRUG | 1500 mg of PF-02413873 oral suspension once daily for 14 days |
| PF-02413873 20 mg QD | DRUG | 20 mg of PF-02413873 oral suspension once daily for 14 days |
| PF-02413873 500 mg QD | DRUG | 500 mg of PF-02413873 oral suspension once daily for 14 days |
| PF-02413873 Placebo | DRUG | PF-0241383 Placebo once daily for 14 days |
Inclusion Criteria: * Healthy women of childbearing potential with a regular menstrual cycle Exclusion Criteria: * Evidence or history of any major disease * Pregnant or nursing women * Requirement for chronic medication